FBRX

Forte is a pre-revenue, clinical-stage biopharma whose entire value rests on one asset: FB102, an anti-CD122 monoclonal antibody. The reported FY2019 revenue of $36K and the resulting P/S of ~8,069x are noise — this is not a business to be valued on sales. It is a pipeline bet, and the pipeline just delivered. The June 2025 celiac Phase 1b was a real read: statistically significant benefit on the composite histological VCIEL endpoint (mean change +0.079 for FB102 vs -1.849 placebo, p=0.0099), a favorable CD3+ IEL result (p=0.0035), a 42% reduction in gluten-challenge GI symptoms, no dropouts, and a clean safety profile with no grade-3+ SAEs in the FB102 arm. In a celiac market the filing describes as ~2.5M diagnosed U.S. patients with no approved treatment, that is a credible signal, and management has already advanced to a Phase 2 with a 2026 topline and a November 2025 FDA IND clearance for a U.S. arm.

The catalyst density is the bull case: Phase 2 celiac topline in 2026, non-segmental vitiligo Phase 1b topline in H1 2026, and an alopecia areata Phase 1b readout in 2026 — three shots on goal within roughly twelve months against a $290M market cap. Strip out the $77.0M cash and the market is paying ~$213M for that optionality, which is not obviously stretched for a de-risked lead program with a broad autoimmune mechanism.